|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 27, 2016 ) Publisher's, 'Neurofibromatoses Type II - Pipeline Review, H1 2016', provides an overview of the Neurofibromatoses Type II pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Other Key Points in Report:
- The report provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type II
- The report reviews pipeline therapeutics for Neurofibromatoses Type II by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neurofibromatoses Type II therapeutics and enlists all their major and minor projects
- The report assesses Neurofibromatoses Type II therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neurofibromatoses Type II
Ask for Sample Report @ http://www.reportsweb.com/inquiry&RW0001242075/sample
Table of Content: An Overview
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Neurofibromatoses Type II Overview 6
Therapeutics Development 7
Pipeline Products for Neurofibromatoses Type II - Overview 7
Pipeline Products for Neurofibromatoses Type II - Comparative Analysis 8
Neurofibromatoses Type II - Therapeutics under Development by Companies 9
Neurofibromatoses Type II - Therapeutics under Investigation by Universities/Institutes 10
Neurofibromatoses Type II - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Neurofibromatoses Type II - Products under Development by Companies 13
Neurofibromatoses Type II - Products under Investigation by Universities/Institutes 14
Neurofibromatoses Type II - Companies Involved in Therapeutics Development 15
Arno Therapeutics, Inc. 15
CalAsia Pharmaceuticals, Inc. 16
Lixte Biotechnology Holdings, Inc. 17
Novartis AG 18
Neurofibromatoses Type II - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001242075/discount
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 27
AR-42 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
everolimus - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
FRAX-597 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
LB-201 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
LB-205 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001242075/buy/2000
About Us:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Email: sales@reportsweb.com
Call: +1-646-491-9876
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
